Scoop: Turing is considering a $100M cash offer for the drug that triggered a national scandal over drug pricing
Turing Pharmaceuticals has received a $100 million offer for the drug that triggered a national uproar over drug price gouging, Endpoints News has learned.
The company, launched by Martin Shkreli before he became a lightning rod in the controversy over extreme drug pricing, was supposed to gather votes today on proposed members of the board at Turing. That vote was scheduled after research chief Eliseo Salinas took over recently as interim CEO as various factions fought for control of the company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.